Global Castration Resistant Prostate Cancer Treatment Market 2020 Research Forecast 2026

Published On: Dec 2019

Format: PDF

Publisher: QY Research

Pages: 96

Report ID: 87574

Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment.  However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
North America dominates the global market for castration resistant prostate cancer treatment due to presence of large prostate cancer population in this region. Moreover, increasing demand of diagnostic test, increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global castration resistant prostate cancer treatment market due to presence of large geriatric population base in European region. Asia-Pacific is considered as an untapped market due to lack of awareness and lack of proper healthcare facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market during the study period due to growing market penetration in this region.
In 2020, the global Castration Resistant Prostate Cancer Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026.

This report focuses on the global Castration Resistant Prostate Cancer Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Castration Resistant Prostate Cancer Treatment development in United States, Europe and China.

The key players covered in this study
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals

Market segment by Type, the product can be split into
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others

Market segment by Application, split into
Hospital
Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Castration Resistant Prostate Cancer Treatment status, future forecast, growth opportunity, key market and key players.
To present the Castration Resistant Prostate Cancer Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Castration Resistant Prostate Cancer Treatment are as follows:
History Year: 2014-2018
Base Year: 2019
Estimated Year: 2019
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type (2015-2026)
1.4.2 Hormonal Therapy
1.4.3 Adding An Anti-Androgen
1.4.4 Stopping An Anti-Androgen
1.4.5 Estrogens
1.4.6 Chemotherapy
1.4.7 Radiation Therapy
1.4.8 Others
1.5 Market by Application
1.5.1 Global Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2026)
1.5.2 Hospital
1.5.3 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Castration Resistant Prostate Cancer Treatment Market Size
2.2 Castration Resistant Prostate Cancer Treatment Growth Trends by Regions
2.2.1 Castration Resistant Prostate Cancer Treatment Market Size by Regions (2015-2026)
2.2.2 Castration Resistant Prostate Cancer Treatment Market Share by Regions (2015-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Castration Resistant Prostate Cancer Treatment Market Size by Manufacturers
3.1.1 Global Castration Resistant Prostate Cancer Treatment Revenue by Manufacturers (2015-2020)
3.1.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Manufacturers (2015-2020)
3.1.3 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Castration Resistant Prostate Cancer Treatment Key Players Head office and Area Served
3.3 Key Players Castration Resistant Prostate Cancer Treatment Product/Solution/Service
3.4 Date of Enter into Castration Resistant Prostate Cancer Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
4.2 Global Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)

5 United States
5.1 United States Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
5.2 Castration Resistant Prostate Cancer Treatment Key Players in United States
5.3 United States Castration Resistant Prostate Cancer Treatment Market Size by Type
5.4 United States Castration Resistant Prostate Cancer Treatment Market Size by Application

6 Europe
6.1 Europe Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
6.2 Castration Resistant Prostate Cancer Treatment Key Players in Europe
6.3 Europe Castration Resistant Prostate Cancer Treatment Market Size by Type
6.4 Europe Castration Resistant Prostate Cancer Treatment Market Size by Application

7 China
7.1 China Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
7.2 Castration Resistant Prostate Cancer Treatment Key Players in China
7.3 China Castration Resistant Prostate Cancer Treatment Market Size by Type
7.4 China Castration Resistant Prostate Cancer Treatment Market Size by Application

8 Japan
8.1 Japan Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
8.2 Castration Resistant Prostate Cancer Treatment Key Players in Japan
8.3 Japan Castration Resistant Prostate Cancer Treatment Market Size by Type
8.4 Japan Castration Resistant Prostate Cancer Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
9.2 Castration Resistant Prostate Cancer Treatment Key Players in Southeast Asia
9.3 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Type
9.4 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Application

10 India
10.1 India Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
10.2 Castration Resistant Prostate Cancer Treatment Key Players in India
10.3 India Castration Resistant Prostate Cancer Treatment Market Size by Type
10.4 India Castration Resistant Prostate Cancer Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
11.2 Castration Resistant Prostate Cancer Treatment Key Players in Central & South America
11.3 Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Type
11.4 Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Application

12 International Players Profiles
12.1 Active Biotech
12.1.1 Active Biotech Company Details
12.1.2 Company Description and Business Overview
12.1.3 Castration Resistant Prostate Cancer Treatment Introduction
12.1.4 Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.1.5 Active Biotech Recent Development
12.2 Diagnocure
12.2.1 Diagnocure Company Details
12.2.2 Company Description and Business Overview
12.2.3 Castration Resistant Prostate Cancer Treatment Introduction
12.2.4 Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.2.5 Diagnocure Recent Development
12.3 Glaxosmithkline
12.3.1 Glaxosmithkline Company Details
12.3.2 Company Description and Business Overview
12.3.3 Castration Resistant Prostate Cancer Treatment Introduction
12.3.4 Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.3.5 Glaxosmithkline Recent Development
12.4 Northwest Biotherapeutics
12.4.1 Northwest Biotherapeutics Company Details
12.4.2 Company Description and Business Overview
12.4.3 Castration Resistant Prostate Cancer Treatment Introduction
12.4.4 Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.4.5 Northwest Biotherapeutics Recent Development
12.5 Millennium Pharmaceuticals
12.5.1 Millennium Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Castration Resistant Prostate Cancer Treatment Introduction
12.5.4 Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.5.5 Millennium Pharmaceuticals Recent Development
12.6 Hologic
12.6.1 Hologic Company Details
12.6.2 Company Description and Business Overview
12.6.3 Castration Resistant Prostate Cancer Treatment Introduction
12.6.4 Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.6.5 Hologic Recent Development
12.7 Spectrum Pharmaceuticals
12.7.1 Spectrum Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Castration Resistant Prostate Cancer Treatment Introduction
12.7.4 Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.7.5 Spectrum Pharmaceuticals Recent Development
12.8 Abbott Laboratories
12.8.1 Abbott Laboratories Company Details
12.8.2 Company Description and Business Overview
12.8.3 Castration Resistant Prostate Cancer Treatment Introduction
12.8.4 Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.8.5 Abbott Laboratories Recent Development
12.9 Bayer Healthcare Pharmaceuticals
12.9.1 Bayer Healthcare Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Castration Resistant Prostate Cancer Treatment Introduction
12.9.4 Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
12.9.5 Bayer Healthcare Pharmaceuticals Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details